No evidence for association of multiple sclerosis with the complement factors C6 and C7

[1]  G. Stewart,et al.  Strong linkage disequilibrium between HLA-Dw2 and and BfS in multiple sclerosis and in the normal population. , 2008, Tissue antigens.

[2]  P. Goodfellow,et al.  HLA typing in the United Kingdom multiple sclerosis genome screen , 1998, Neurogenetics.

[3]  H. Lassmann,et al.  Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination , 1998, Annals of neurology.

[4]  M. Daly,et al.  Genomewide scan of multiple sclerosis in Finnish multiplex families. , 1997, American journal of human genetics.

[5]  Leonid Kruglyak,et al.  The use of a genetic map of biallelic markers in linkage studies , 1997, Nature Genetics.

[6]  R. Würzner,et al.  DNA haplotypes of the complement C6 and C7 genes associated with deficiencies of the seventh component; and a new DNA polymorphism in C7 exon 13 , 1997, Annals of human genetics.

[7]  N. Morton,et al.  A metric map of humans: 23,500 loci in 850 bands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  W J Ewens,et al.  The TDT and other family-based tests for linkage disequilibrium and association. , 1996, American journal of human genetics.

[9]  F. Luft,et al.  Oligonucleotide ligation assay (OLA) for the diagnosis of familial hypercholesterolemia , 1996, Nature Biotechnology.

[10]  D. Hinds,et al.  A full genome search in multiple sclerosis , 1996, Nature Genetics.

[11]  Leena Peltonen,et al.  A putative vulnerability locus to multiple sclerosis maps to 5p14–p12 in a region syntenic to the murine locus Eae2 , 1996, Nature Genetics.

[12]  J. Haines,et al.  A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex , 1996, Nature Genetics.

[13]  P. Goodfellow,et al.  A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 , 1996, Nature Genetics.

[14]  L Kruglyak,et al.  High-resolution genetic mapping of complex traits. , 1995, American journal of human genetics.

[15]  P. Lachmann,et al.  Complement component C6 and C7 haplotypes associated with deficiencies of C6 , 1995, Annals of human genetics.

[16]  D. J. Unsworth,et al.  DNA polymorphisms of the complement C6 and C7 genes , 1995, Annals of human genetics.

[17]  M. Chen,et al.  Vitronectin and Integrin Vitronectin Receptor Localization in Multiple Sclerosis Lesions , 1995, Journal of neuropathology and experimental neurology.

[18]  E. Winn-Deen,et al.  High-density multiplex detection of nucleic acid sequences: oligonucleotide ligation assay and sequence-coded separation. , 1994, Nucleic acids research.

[19]  M. Hobart.  Structure and gross arrangement of the C6 and C7 genes , 1993 .

[20]  W. Ewens,et al.  Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). , 1993, American journal of human genetics.

[21]  G. Füst,et al.  Sclerosis multiplex in gypsies , 1991, Acta neurologica Scandinavica.

[22]  G. Ebers,et al.  Allele frequencies of the third component of complement (C3) in MS patients. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[23]  M. Esiri,et al.  Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. , 1991, Brain : a journal of neurology.

[24]  U Landegren,et al.  Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[25]  N. Risch.  Linkage strategies for genetically complex traits. I. Multilocus models. , 1990, American journal of human genetics.

[26]  A. Campbell,et al.  IMMUNOCYTOCHEMICAL LOCALIZATION OF THE TERMINAL COMPLEMENT COMPLEX IN MULTIPLE SCLEROSIS , 1989, Neuropathology and applied neurobiology.

[27]  A. Campbell,et al.  Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement , 1989, Nature.

[28]  A. Campbell,et al.  Normal rat serum cytotoxicity against syngeneic oligodendrocytes Complement activation and attack in the absence of anti-myelin antibodies , 1989, Journal of the Neurological Sciences.

[29]  U Landegren,et al.  A ligase-mediated gene detection technique. , 1988, Science.

[30]  W. Mcdonald,et al.  Multiple sclerosis in north-east Scotland. An association with HLA-DQw1. , 1987, Brain : a journal of neurology.

[31]  A. Campbell,et al.  Cerebrospinal fluid C9 in demyelinating disease , 1986, Neurology.

[32]  R. Nájera,et al.  Immunogenetic profile of multiple sclerosis in Mexicans. , 1986, Human immunology.

[33]  K. Joiner,et al.  Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis. , 1986, Journal of immunology.

[34]  J. Tschopp,et al.  Monoclonal Antibodies Recognizing a Neoantigen of Poly(C9) Detect the Human Terminal Complement Complex in Tissue and Plasma , 1985, Scandinavian journal of immunology.

[35]  H. Sørensen,et al.  C3 Polymorphism and circulating immune complexes in patients with multiple sclerosis , 1980, Acta neurologica Scandinavica.

[36]  W. Brzosko,et al.  Immunofluorescence study of brain plaques from two patients with multiple sclerosis , 1977, Neurology.

[37]  W. Luboldt,et al.  C2 HYPOCOMPLEMENTÆMIA IN MULTIPLE SCLEROSIS , 1976, The Lancet.

[38]  C. Lumsden.  The immunogenesis of the multiple sclerosis plaque. , 1971, Brain research.

[39]  A. J. Schafer,et al.  Microbial natural products: Alive and well in 1998 , 1998, Nature Biotechnology.

[40]  E. Winn-Deen,et al.  Fluorescence‐based oligonucleotide ligation assay for analysis of cystic fibrosis transmembrane conductance regulator gene mutations , 1995, Human mutation.

[41]  F. Barany.  Genetic disease detection and DNA amplification using cloned thermostable ligase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.